Ferritin Management Guidelines for Hereditary Hemochromatosis

Target Serum Ferritin Levels

• The recommended serum ferritin range for both induction and maintenance therapy is 50–100 µg/L【1】.

Induction Phase

Target Goal

• The European Association for the Study of the Liver (EASL) 2022 guideline sets a target ferritin of ≈50 µg/L during the induction phase【1】.

Phlebotomy Regimen

• Perform weekly or bi‑weekly phlebotomy (≈400–500 mL per session) until the target ferritin is achieved【1】.

Monitoring Schedule

• Serum ferritin should be measured monthly or after every fourth phlebotomy【1】.
• When ferritin falls below 200 µg/L, increase monitoring to every 1–2 phlebotomy sessions to avoid overshooting into iron deficiency【1】.
• Hemoglobin must be checked before each phlebotomy【1】.

Hemoglobin Safety Thresholds

• If hemoglobin drops below 12 g/dL, reduce the phlebotomy frequency or volume【1】.
• If hemoglobin drops below 11 g/dL, temporarily discontinue phlebotomy and reassess with laboratory and clinical evaluation【1】.

Maintenance Phase

Target Goal

• Both the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) 2022 guidelines recommend maintaining ferritin within 50–100 µg/L【1】.

Phlebotomy Frequency

• Schedule phlebotomy every 1–4 months, individualized according to each patient’s iron accumulation rate【1】.

Monitoring Schedule

• Serum ferritin should be re‑checked every 6 months to confirm the target range is sustained【1】.
• Adjust the phlebotomy schedule based on ferritin trends; untreated patients typically experience an average ferritin rise of ~100 µg/L per year【1】.

Avoiding Overtreatment

• Ferritin should not be reduced below 50 µg/L, as this is the physiologic lower limit for adequate iron stores【1】.
• Ferritin < 50 µg/L leads to further suppression of hepcidin and increased dietary iron absorption, even in hemochromatosis【1】.
• Ferritin < 20 µg/L markedly enhances non‑heme iron absorption and can precipitate symptomatic iron deficiency【1】.

Transferrin Saturation Considerations

• Periodic transferrin saturation monitoring is advised, although specific target levels are not evidence‑based【1】.
• Saturation may remain elevated (>50 %) despite ferritin being within the target range【1】.
• Observational data suggest that general and joint symptoms may be linked to long‑term exposure to transferrin saturation > 50 % regardless of achieving ferritin < 50 µg/L【1】.

Unexpected Ferritin Fluctuations

• Any unexplained changes in serum ferritin or transferrin saturation should be investigated, as significant fluctuations are atypical for hereditary hemochromatosis【1】.
• Potential causes include concurrent inflammation, infection, or other pathology【1】.

Adjunctive Nutrient Monitoring

• Periodic assessment of plasma folate and cobalamin is recommended, especially for patients undergoing numerous venesections【1】.
• Initiate vitamin supplementation when deficiencies are identified【1】.

Optimal Ferritin Levels for Patients with Hemochromatosis

Treatment Phases and Target Ferritin Levels

• The European Association for the Study of the Liver recommends a target ferritin level of 50 μg/L during the induction phase and 50-100 μg/L during the maintenance phase for patients with hemochromatosis 2
• The American Association for the Study of Liver Diseases recommends a target ferritin level of 50-100 μg/L for both phases of treatment for patients with hemochromatosis 3
• The British Society for Haematology recommends a target ferritin level of 20-30 μg/L for induction and <50 μg/L for maintenance for patients with hemochromatosis 3
• Weekly or biweekly phlebotomy (400-500 ml) should be performed until the target ferritin level is reached, with serum ferritin measured monthly or after every 4th phlebotomy 4, 5
• When ferritin decreases below 200 μg/L, it should be checked every 1-2 phlebotomy sessions to avoid iron deficiency 2

Important Monitoring Considerations

• Hemoglobin levels should be checked before each phlebotomy session, and if hemoglobin falls below 12 g/dL, reduce phlebotomy frequency or volume 2
• If hemoglobin falls below 11 g/dL, temporarily discontinue phlebotomy to prevent anemia 2
• Monitor transferrin saturation, although evidence-based target levels are lacking, as observational data suggest that joint symptoms may persist with transferrin saturation >50% even when ferritin is <50 μg/L 2, 6

Special Considerations for Elderly Patients

• More relaxed targets (ferritin <200 μg/L for women and <300 μg/L for men) may be better tolerated in elderly patients during the maintenance phase, reflecting clinical practice but based on expert opinion rather than clinical studies 7

Dietary and Lifestyle Recommendations

• Dietary modifications should not substitute for phlebotomy therapy, and patients should avoid iron supplementation and iron-fortified foods, limit red meat consumption, and avoid supplemental vitamin C, especially before iron depletion 8
• Restrict alcohol intake, particularly during the iron depletion phase, and patients with cirrhosis should abstain from alcohol completely to reduce the risk of complications associated with iron overload 8